BIOBRAN MGN-3
Clinical Indication
Adjuvant to cancer treatment
Comments
Cancer Research UK statement
Do not prescribe
Drugs not recommended for use in LLR because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.